190 related articles for article (PubMed ID: 17150335)
1. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
[TBL] [Abstract][Full Text] [Related]
2. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.
Güzey C; Scordo MG; Spina E; Landsem VM; Spigset O
Eur J Clin Pharmacol; 2007 Mar; 63(3):233-41. PubMed ID: 17225991
[TBL] [Abstract][Full Text] [Related]
4. Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.
Costa A; Riedel M; Müller U; Möller HJ; Ettinger U
Synapse; 2011 Oct; 65(10):998-1005. PubMed ID: 21404331
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes.
Gassó P; Mas S; Crescenti A; Alvarez S; Parramon G; Garcia-Rizo C; Parellada E; Bernardo M; Lafuente A
Psychiatry Res; 2010 Jan; 175(1-2):173-5. PubMed ID: 19892410
[TBL] [Abstract][Full Text] [Related]
6. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.
van Dyck CH; Malison RT; Jacobsen LK; Seibyl JP; Staley JK; Laruelle M; Baldwin RM; Innis RB; Gelernter J
J Nucl Med; 2005 May; 46(5):745-51. PubMed ID: 15872345
[TBL] [Abstract][Full Text] [Related]
7. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
8. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3.
van de Giessen E; de Win MM; Tanck MW; van den Brink W; Baas F; Booij J
J Nucl Med; 2009 Jan; 50(1):45-52. PubMed ID: 19091889
[TBL] [Abstract][Full Text] [Related]
9. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans.
Martinez D; Gelernter J; Abi-Dargham A; van Dyck CH; Kegeles L; Innis RB; Laruelle M
Neuropsychopharmacology; 2001 May; 24(5):553-60. PubMed ID: 11282255
[TBL] [Abstract][Full Text] [Related]
10. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective
Hellwig S; Frings L; Masuch A; Vach W; Domschke K; Normann C; Meyer PT
J Neural Transm (Vienna); 2018 Jun; 125(6):995-1005. PubMed ID: 29476250
[TBL] [Abstract][Full Text] [Related]
12. Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis.
Faraone SV; Spencer TJ; Madras BK; Zhang-James Y; Biederman J
Mol Psychiatry; 2014 Aug; 19(8):880-9. PubMed ID: 24061496
[TBL] [Abstract][Full Text] [Related]
13. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia.
Xu M; Xing Q; Li S; Zheng Y; Wu S; Gao R; Yu L; Guo T; Yang Y; Liu J; Zhang A; Zhao X; He G; Zhou J; Wang L; Xuan J; Du J; Li X; Feng G; Lin Z; Xu Y; St Clair D; Lin Z; He L
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1026-32. PubMed ID: 20580759
[TBL] [Abstract][Full Text] [Related]
14. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.
Mateos JJ; Lomeña F; Parellada E; Mireia F; Fernandez-Egea E; Pavia J; Prats A; Pons F; Bernardo M
Psychopharmacology (Berl); 2007 Apr; 191(3):805-11. PubMed ID: 17019564
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gasso P; Deulofeu R; Mane A; Catalan R; Carne X
Psychiatry Res; 2008 Nov; 161(2):131-41. PubMed ID: 18922583
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between VNTR polymorphism of dopamine transporter gene (SLC6A3) and schizophrenia in a Brazilian sample.
Cordeiro Q; Talkowski M; Wood J; Ikenaga E; Vallada H
Arq Neuropsiquiatr; 2004 Dec; 62(4):973-6. PubMed ID: 15608954
[TBL] [Abstract][Full Text] [Related]
17. Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability.
Kasparbauer AM; Rujescu D; Riedel M; Pogarell O; Costa A; Meindl T; la Fougère C; Ettinger U
Neuropsychopharmacology; 2015 Feb; 40(3):736-45. PubMed ID: 25220215
[TBL] [Abstract][Full Text] [Related]
18. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.
Szekeres G; Kéri S; Juhász A; Rimanóczy A; Szendi I; Czimmer C; Janka Z
Am J Med Genet B Neuropsychiatr Genet; 2004 Jan; 124B(1):1-5. PubMed ID: 14681904
[TBL] [Abstract][Full Text] [Related]
19. Prediction of dopamine transporter binding availability by genotype: a preliminary report.
Jacobsen LK; Staley JK; Zoghbi SS; Seibyl JP; Kosten TR; Innis RB; Gelernter J
Am J Psychiatry; 2000 Oct; 157(10):1700-3. PubMed ID: 11007732
[TBL] [Abstract][Full Text] [Related]
20. Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele.
Krause J; Dresel SH; Krause KH; La Fougère C; Zill P; Ackenheil M
World J Biol Psychiatry; 2006; 7(3):152-7. PubMed ID: 16861140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
